This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Menu

HomeEfficacy

Phase 3 Study Primary Endpoints

Success in ISGA: Clear or almost clearStudy Design

Phase 3 Study Secondary and Other Endpoints

ISGA clear or almost clearTime to ISGA successPhase 3 Study: Other EndpointsPruritusQuality of life assessmentsInfant Study: Exploratory EndpointsISGA clear or almost clear%BSA, EASI & POEM52-Week TrialSafety DataSafety DataPhase 3 Study Adverse Reactions*Pivotal trial & 48-week extension study Adverse ReactionsOpen-Label Safety Extension Study*Open-Label Safety Extension Study Rescue Therapy EndpointStudy designInfant Safety Study**Adverse ReactionsStudy design and Demographics52-Week TrialReal PatientsReal patient case reportsReal patient case studiesNana's experience with EucrisaBraxton's testimonialHand and fingerFace and neckOtherHand and finger5-yr-old Caucasian female - hands8-yr-old Caucasian female - hands15-yr-old Caucasian male - hand55-yr-old Caucasian female - hand64-yr-old Caucasian female - thumb70-yr-old Caucasian male - thumbFace and neck15-yr-old Caucasian male - chin18-yr-old Hispanic female - face and neck75-yr-old Caucasian male - faceOther39-yr-old Asian male - arm44-yr-old African American female - legs72-yr-old Caucasian female - legDosingSavings & SupportSavings & SupportEventsMaterialsVideosCopay CardsCost and Coverage
Prescribing InformationPatient Information Indication Patient Site
Safety DataSafety profile established in 5 studies, including pivotal and open-label safety extension studies, and an open-label infant safety studyInfant Open-Label Safety trial in patients aged 3 to <24 months2

An open-label, single arm study to evaluate the safety of EUCRISA in 137 infants aged 3 to <24 months with mild-to-moderate atopic dermatitis (AD).

STUDY DESIGN OVERVIEWPhase 4, multicenter, open-label single-arm study to evaluate the safety of crisaborole ointment, 2%.Patients were excluded from the PK cohort if they had lesions below their wrists and ankles or within 2 cm of the mouth.
    Crisaborole  
Non-PK Cohort 
n = 116		 PK Cohort 
n = 21		 Total 
n = 137
Study Demographics

Primary endpoints

  • Incidence of treatment-emergent adverse events (TEAEs), including site reactions and serious AEs
  • Clinically significant changes in height, weight, vital signs, physical exam, ECG, clinical laboratory parameters
Exploratory PK endpoints
  • Crisaborole maximum observed plasma concentration (Cmax)
  • Crisaborole time to reach maximum observed plasma concentration (Tmax)
  • Crisaborole area under plasma concentration-time profile for the dosing interval (AUCtau)
  • Propylene glycol concentrations
Exploratory efficacy endpoints
  • Proportion of patients achieving ISGA success (defined as Clear [0] or Almost Clear [1] with ≥2-grade improvement from baseline)
  • Proportion of patients who achieved ISGA Clear or Almost Clear
  • Percent change from baseline in EASI score
  • Change from baseline in %BSA
  • Change from baseline in total POEM
Study Population
  • Non-PK cohort: mild to moderate AD (ISGA 2 or 3) with ≥5% treatable %BSA, excluding scalp
  • PK cohort: Moderate AD (ISGA 3) with ≥35% treatable %BSA, excluding scalp
Treatment
  • Crisaborole ointment, 2%, BID applied to all treatable AD-involved areas identified at Baseline/Day 1 and any new AD-involved areas that appeared following Baseline/Day 1
  • Non-PK cohort: Baseline AM dosing at study site followed by BID dosing at home from Baseline PM dose through Day 28
  • PK cohort: BID dosing at study site from Baseline to Day 8 AM dose; BID dosing at home from Day 8 PM dose through Day 28
Limitations
  • Outcomes were reported by a caregiver or investigator
  • Open-label study without a comparator group
Age (months)
Scroll left to view table
3 to < 9, n (%) 36 (31.0) 7 (33.3) 43 (31.4)
9 to < 24, n (%) 80 (69.0) 14 (66.7) 94 (68.6)
Mean (SD) 13.7 (6.41) 12.7 (6.58) 13.6 (6.42)
Median (range) 13.5 (3–23) 13.0 (3–23) 13.0 (3–23)
Sex, n (%)
Scroll left to view table
Male 75 (64.7) 13 (61.9) 88 (64.2)
Female 41 (35.3) 8 (38.1) 49 (35.8)
Race, n (%)
Scroll left to view table
White 71 (61.2) 13 (61.9) 84 (61.3)
Black or African American  9 (7.8) 2 (9.5) 11 (8.0)
Asian 23 (19.8) 4 (19.0) 27 (19.7)
American Indian or Alaskan native 1 (0.9) 0 1 (0.7)
Native Hawaiian or other Pacific Islander 1 (0.9) 0 1 (0.7)
Multiracial 11 (9.5) 2 (9.5) 13 (9.5)
ISGA
Scroll left to view table
2 – Mild, n (%) 52 (44.8) 0 52 (38.0)
3 – Moderate, n (%) 64 (55.2) 20 (95.2) 84 (61.3)
4 – Severe,a n (%) 0 1 (4.8) 1 (0.7)
Mean (SD) 2.6 (0.50) 3.0 (0.22) 2.6 (0.50)
Median (range) 3.0 (2–3) 3.0 (3–4) 3.0 (2–4)
POEM total score
Scroll left to view table
Mean (SD) 13.9 (5.86) 19.7 (5.18) 14.8 (6.12)
Median (range) 14.0 (1–24) 20.0 (9–27) 15.0 (1–27)
EASI score
Scroll left to view table
Mean (SD) 10.4 (8.16) 19.8 (4.42) 11.8 (8.41)
Median (range) 7.8 (1.6–38.8) 19.5 (12.5–29.2) 8.9 (1.6–38.8)
%BSA
Scroll left to view table
Mean (SD) 23.5 (20.13) 53.5 (12.61) 28.1 (22.00)
Median (range) 15.5 (5.0–94.0) 56.0 (35.0–79.0) 19.0 (5.0–94.0)
Duration Since Onset (months)
Scroll left to view table
Mean (SD) 10.4 (6.44) 9.1 (5.48) 10.2 (6.3)
Median (range) 9.4 (0.03–23.8) 8.1 (1.4–21.0) 8.6 (0.03–23.8)
Medical History of Other Atopic Conditions, b n (%) 
Scroll left to view table
  21 (18.1)     1 (4.8) 22 (16.1)
Prior Medication Use, n (%)
Scroll left to view table
TCS 63 (54.3) 9 (49.2) 72 (52.6)
TCI 2 (1.7) 0 2 (1.5)
%BSA=percentage of treatable body surface area; EASI=Eczema Area and Severity Index; ISGA=Investigator's Static Global Assessment; PK=pharmacokinetics; POEM=Patient-Oriented Eczema Measure; SD=standard deviation; TCI=topical calcinerin inhibitor; TCS=topical corticosteroid.Protocol deviation.Includes conditions, such as asthma, food allergies, and allergic/seasonal rhinitis.
ReferencesEUCRISA® (crisaborole) Full Prescribing Information. April 2023.Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.
Safety Data
If babies could talk, what would they tell you?

Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him

 Watch JP's story Loading

Not an actual patient

Phase III Study Safety Data

Find out more about EUCRISA's adverse event profile in patients 2 years and older from the pivotal studies

Learn more Loading Rescue Therapy Endpoint

Read about rescue therapy in the 48 week Open-Label Safety Extension study

Learn more Loading Proportion of patients with ISGA Clear or Almost Clear

Find out more about the proportion of patients aged 2 years and older who achieved ISGA clear or almost clear at day 29 from the Phase III trial's secondary endpoint

Learn more Loading Exploratory Pruritus Endpoint

Find out more about the time to relief in pruritus as found in the Phase III study's exploratory endpoint

 Learn more Loading Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

 Learn more Loading
Copay Cards

*Eligible patients pay as little as $10​​​​​​

Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance. Download Copay cards Loading
Savings & Support Program

A savings and support program for your patients to help them with their access to EUCRISA

See resources Loading
Order Samples

Register or sign in to check availability and request samples.

Order now Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-EUC-USA-0066
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-EUC-USA-0032
INDICATION

EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

Indication EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Important Safety Information

Contraindications

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

Warnings and Precautions

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

Adverse Reactions

The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

Please see Full Prescribing Information and Patient Information

Indication EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.Important Safety Information Contraindications

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

Warnings and Precautions

Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

Adverse Reactions

The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

Please see Full Prescribing Information and Patient Information. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut. IndicationEUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.